Schizophrenia

Godfrey Pearlson sat down at APA 2019 to discuss his opinion on what the most significant recent advances in neuropsychiatry have been and how they have impacted practice.

Pear Therapeutics and Novartis presented findings from their study exploring the use of digital therapies in addition to traditional treatment in patients with schizophrenia.

The investigative drug SEP-363856 has been evidenced in a phase 2 trial to reduced hospitalized patient symptoms and severity.

The selective serotonin inverse agonist, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy.

A retroactive review of patients referred to a psychiatric consultant found that most patients left with a different diagnosis.

Both long-acting injectable treatments produced statistically significant and clinically meaningful improvements.

The antipsyhoctic could receive a new indication in 2019, and though the field of bipolar disorder care is far from perfect, it should improve with this addition.

A retrospective study showed which patients with substance use disorder may have less successful antiepileptic drug treatment.

A more multidisciplinary, collaborative care effort for these patients can result in more active monitoring and productive clinical care.